Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Palisade Bio
Biotech
Palisade's stock collapses as sole asset flunks phase 2 GI trial
Palisade Bio has ended development of its only drug in one of two potential indications after it failed to reduce adhesions after bowel surgery.
James Waldron
Aug 9, 2023 10:35am
Former Roche pharma head to be new Bayer CEO—Chutes & Ladders
Feb 10, 2023 9:30am
BIO CEO out the door—Chutes & Ladders
Oct 14, 2022 9:30am
With cash evaporating quickly, Palisade Bio cuts 20% of staff
Sep 15, 2022 4:50pm
Seneca Biopharma merges with Leading BioSciences
Dec 17, 2020 8:18am